With Quick to Clinic™ viral vector services, you can get to released drug product for IND six months faster than standard process development. Set the foundation for commercial success by utilizing our end-to-end, commercial-ready manufacturing process that’s inclusive of all raw materials, analytical testing, phase appropriate regulatory support, and commercial-use licenses. Quick to Clinic™ viral vector services offers:
- 20 manufacturing platforms
- More than 50 drug substance and product suites
- Four late-phase commercial manufacturing facilities
- Expansive global network offering 650,000 sq. ft. capacity available today
Simply provide details around your gene of interest and any known product specifications and let Quick to Clinic™ viral vector services do the rest.